UniProtKB/SwissProt variant VAR

Variant information

Variant position:

1697

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Cysteine (C) to Arginine (R) at position 1697 (C1697R, p.Cys1697Arg).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from medium size and polar (C) to large size and basic (R)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In ovarian cancer.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs80356993 [ dbSNP | Ensembl ]

Sequence information

Variant position:

1697

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

1863

The length of the canonical sequence.

Location on the sequence:

TNLITEETTHVVMKTDAEFV C ERTLKYFLGIAGGKWVVSYF

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TNLITEETTH-VVMKTDAEFVCERTLKYFLGIAGGKWVVSYF

Gorilla                       TNLITEETTH-VVMKTDAEFVCERTLKYFLGIAGGKWVVSY

Rhesus macaque                TNLISEETTH-VVMKTDAEFVCERTLKYFLGIAGGKWVVSY

Chimpanzee                    TNLITEETTH-VVMKTDAEFVCERTLKYFLGIAGGKWVVSY

Mouse                         TDAITEETTH-VIIKTDAEFVCERTLKYFLGIAGGKWIVSY

Rat                           TDVITEETTH-VIIKTDAEFVCERTLKYFLGIAGGKWIVSY

Bovine                        TNLITEETTH-VIMKTDPEFVCERTLKYFLGIAGGKWVVSY

Caenorhabditis elegans        ---VNEHTTHLVMMNSEGRSISQKSTAYLYAIARKCVIVGR

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 1863	Breast cancer type 1 susceptibility protein
Domain	1642 – 1736	BRCT 1
Alternative sequence	64 – 1863	Missing. In isoform 2.
Mutagenesis	1700 – 1700	T -> A. Strongly reduces affinity for a BRIP1 phosphopeptide.
Mutagenesis	1702 – 1702	K -> M. Abolishes interaction with BRIP1.
Beta strand	1695 – 1697

Literature citations

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Malander S.; Ridderheim M.; Masbaeck A.; Loman N.; Kristoffersson U.; Olsson H.; Nilbert M.; Borg A.;
Eur. J. Cancer 40:422-428(2004)
Cited for: VARIANTS OVARIAN CANCER GLY-61; THR-1411; ARG-1697 AND TRP-1699;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P38398: Variant p.Cys1697Arg